ID   JHC7
AC   CVCL_L154
SY   Johns Hopkins Chordoma line 7
DR   ATCC; CRL-3267
DR   cancercelllines; CVCL_L154
DR   Cell_Model_Passport; SIDM01802
DR   Cosmic; 2663862
DR   DepMap; ACH-001955
DR   Wikidata; Q54898635
RX   CelloPub=CLPUB00390;
RX   PubMed=21699479;
RX   PubMed=27102572;
RX   PubMed=28835717;
WW   Info; Chordoma Foundation; -; https://www.chordomafoundation.org/researchers/disease-models/jhc7/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: ~5 days (PubMed=21699479); 3.5-4 days (Chordoma Foundation).
CC   HLA typing: A*24 (Chordoma Foundation).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg213Leu (c.638G>T); ClinVar=VCV000376650; Zygosity=Unspecified (DepMap=ACH-001955).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Genomics; Whole genome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; CNV analysis.
CC   Anecdotal: Established in 2009 from a chordoma tumor sample originating from Susan L. Garbett who wrote about her successful fight against cancer in an autobiographical book (CelloPub=CLPUB00390).
CC   Derived from site: In situ; Bone, sacrum; UBERON=UBERON_0003690.
ST   Source(s): ATCC=CRL-3267; PubMed=27102572; PubMed=28835717
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 12
ST   D19S433: 13,13.2
ST   D21S11: 27,31.2
ST   D2S1338: 18,20
ST   D3S1358: 17
ST   D5S818: 13
ST   D7S820: 7,10
ST   D8S1179: 13,14
ST   FGA: 21,23
ST   Penta D: 6,11
ST   Penta E: 15
ST   TH01: 6,8
ST   TPOX: 10,11
ST   vWA: 17
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 10-04-25; Version: 25
//
RX   CelloPub=CLPUB00390;
RA   Garbett S.L.;
RT   "Confronting chordoma cancer. An uncommon journey.";
RL   (In book) ISBN 9780983617198; pp.1-264; Parquetry Press; Tallevast; USA (2015).
//
RX   PubMed=21699479; DOI=10.3171/2011.5.JNS11185; PMCID=PMC4273567;
RA   Hsu W., Mohyeldin A., Shah S.R., ap Rhys C.M.J., Johnson L.F.,
RA   Sedora-Roman N.I., Kosztowski T.A., Awad O.A., McCarthy E.F.,
RA   Loeb D.M., Wolinsky J.-P., Gokaslan Z.L., Quinones-Hinojosa A.;
RT   "Generation of chordoma cell line JHC7 and the identification of
RT   Brachyury as a novel molecular target.";
RL   J. Neurosurg. 115:760-769(2011).
//
RX   PubMed=27102572; DOI=10.1002/path.4729; PMCID=PMC4922416;
RA   Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H.,
RA   Zuercher W.J., Turlais F., Ye H.-T., Leite A.P., Smith J.A., Leithner A.,
RA   Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R.,
RA   Strauss S.J., Pillay N., Flanagan A.M.;
RT   "EGFR inhibitors identified as a potential treatment for chordoma in a
RT   focused compound screen.";
RL   J. Pathol. 239:320-334(2016).
//
RX   PubMed=28835717; DOI=10.1038/s41598-017-10044-3; PMCID=PMC5569021;
RA   Bosotti R., Magnaghi P., Di Bella S., Cozzi L., Cusi C., Bozzi F.,
RA   Beltrami N., Carapezza G., Ballinari D., Amboldi N., Lupi R.,
RA   Somaschini A., Raddrizzani L., Salom B., Galvani A., Stacchiotti S.,
RA   Tamborini E., Isacchi A.;
RT   "Establishment and genomic characterization of the new chordoma cell
RT   line Chor-IN-1.";
RL   Sci. Rep. 7:9226-9226(2017).
//